A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure

NCT07218627 ·Status: RECRUITING ·Phase: PHASE1

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

NCT05096143 ·Status: COMPLETED

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371 ·Status: RECRUITING ·Phase: PHASE2

Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction

NCT04397302 ·Status: COMPLETED

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779 ·Status: RECRUITING ·Phase: PHASE2

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

NCT04890548 ·Status: WITHDRAWN ·Phase: PHASE1

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

NCT04986202 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Tezosentan in Acute Heart Failure

NCT00525707 ·Status: COMPLETED ·Phase: PHASE3

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

NCT04210375 ·Status: COMPLETED ·Phase: PHASE1

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

NCT07192341 ·Status: RECRUITING ·Phase: NA

Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction

NCT05477498 ·Status: WITHDRAWN ·Phase: PHASE4

Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.

NCT05448872 ·Status: COMPLETED

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

NCT05194111 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of CK-1827452 Infusion in Stable Heart Failure

NCT00624442 ·Status: COMPLETED ·Phase: PHASE2

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

NCT02861534 ·Status: COMPLETED ·Phase: PHASE3

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

NCT03547583 ·Status: COMPLETED ·Phase: PHASE2

A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]

NCT01599117 ·Status: UNKNOWN ·Phase: PHASE3

Virtual Care to Improve Heart Failure Outcomes (VITAL-HF)

NCT05602454 ·Status: COMPLETED ·Phase: NA

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

NCT02957409 ·Status: COMPLETED

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

NCT05312021 ·Status: WITHDRAWN ·Phase: PHASE2

Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction

NCT04475042 ·Status: UNKNOWN ·Phase: PHASE2

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

NCT03785405 ·Status: COMPLETED ·Phase: PHASE3

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

NCT03300427 ·Status: COMPLETED ·Phase: PHASE4

Phase Ib/IIa Trial With AC01 in Patients With HFrEF

NCT05642507 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT05139615 ·Status: TERMINATED ·Phase: PHASE2